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There are no reliable predictors of response to treatment with capsaicin. Given that capsaicin application causes heat sensation,
differences in quantitative thermal testing (QTT) profiles may predict treatment response. The aim of this study was to determine
whether different QTT profiles could predict treatment outcomes in patients with localized peripheral neuropathic pain (PeLNP).
We obtained from medical records QTT results and treatment outcomes of 55 patients treated between 2010 and 2013. Warm
sensation threshold (WST) and heat pain threshold (HPT) values were assessed at baseline at the treatment site and in the
asymptomatic, contralateral area. Responders were defined as those who achieved a > 30% decrease in pain lasting > 30 days.
Two distinct groups were identified based on differences in QTT profiles. Most patients (27/31; 87.1%) with a homogenous profile
were nonresponders. By contrast, more than half of the patients (13/24, 54.2%) with a nonhomogenous profile were responders
(𝑝 = 0.0028). A nonhomogenous QTT profile appears to be predictive of response to capsaicin. We hypothesize patients with a
partial loss of cutaneous nerve fibers or receptors are more likely to respond. By contrast, when severe nerve damage or normal
cutaneous sensations are present, the pain is likely due to central sensitization and thus not responsive to capsaicin. Prospective
studies with larger patient samples are needed to confirm this hypothesis.
1. Introduction
Neuropathic pain is a chronic condition that is very difficult
to treat [1], and only small improvements in treatment efficacy
have been achieved in the last decade. However, one of the
most promising treatments for peripheral neuropathic pain
(PeNP) developed in recent years is the capsaicin 8% patch
(CP8%) (QutenzaTM). This patch delivers capsaicin into the
skin and clinical trials have shown that it can provide up to
12 weeks of PeNP relief with a single topical patch application
[2–4].
Capsaicin works by directly targeting, with a highly
selective agonism, the transient receptor potential vanilloid 1
(TRPV1) receptor, which is primarily present in C-fibers and
in some A𝛿-fibers. High-concentration capsaicin activates
TRPV1 channels by overstimulating the nociceptors, result-
ing in the defunctionalization of the nociceptor nerve fibers
and thereby reducing spontaneous nerve activity, leading to
a loss of responsiveness. After defunctionalization, patients
perceive a decrease in PeNP [5–7], which is frequently
referred to as “desensitization.”
The EuropeanMedical Agency (EMA) has recommended
that CP8% be applied by a doctor or other healthcare profes-
sionals under the supervision of a doctor [8]. However, this
recommendation limits treatment options, primarily because
it depends on the availability of treatment at outpatient
Hindawi Publishing Corporation
Pain Research and Treatment
Volume 2017, Article ID 7425907, 11 pages
http://dx.doi.org/10.1155/2017/7425907
2 Pain Research and Treatment
clinics. This requirement also makes treatment more expen-
sive. In addition, the indirect costs of personnel and other
materials must be added to the direct cost of CP8% [9]. As
a result, many patients who could benefit from treatment
may not be treated due to affordability issues. The number-
needed-to-treat (NNT) for CP8% is high [10]. Given the
aforementioned high cost of treatment, the patch should be
applied only to those most likely to benefit from improve-
ment. However, to date, no clear predictors of treatment
response in patients with PeNP have been identified, despite
recent efforts to do so [11–13].
Given that capsaicin affects unmyelinated or slightly
myelinated fibers and studies have shown that the CP8%
patch involves heat sensation [6], we hypothesized that
quantitative thermal testing (QTT) could be a potential
predictor of treatment response. To investigate this question,
we performed a retrospective study of clinical records to
assess the QTT profiles of patients who underwent capsaicin
treatment for PeLNP. Our main aim was to compare the
baselineQTT profiles to determine whether any of these were
associated with treatment response.
2. Material and Methods
This was a retrospective analysis of all patients treated with
the CP8% patch for PeNP at our pain clinic between 2010 and
2013. From patient medical records, we obtained QTT results
and treatment outcomes (response versus nonresponse) for
all patients. All procedures were performed according to
clinical protocols in place at our institution during the study
period.
2.1. Patients. Since late 2010, all patients presenting at our
pain clinic with a high suspicion for PeNP have been asked to
complete theDouleur Neuropathique 4 Scale (DN4), followed
by consultations with a pain physician and a neurophysi-
ologist for complete neurological assessment. Based on this
evaluation, patients are classified into one of the following
pain categories: (1) postherpetic neuralgia (PHN) and (2)
chronic postsurgical pain (CPSP), or type I or II complex
regional pain syndrome (CRPS). PeNP is considered possible
when the patient meets the criteria given in the International
Association for the Study of Pain (IASP) recommendations
[14]. In cases in which the PeNP is confined to a single, local-
ized area, it is classified as localized peripheral neuropathic
pain (PeLNP) [15]. Patients with PeLNP are eligible to choose
either CP8% or lidocaine plaster for topical treatment.
2.2. Establishing the Area to Be Treated. Prior to treatment,
a discontinuous line is drawn with a permanent-ink marker
on the skin to mark the boundaries between the painful area
(identified by the patient as hyperalgesia or allodynia) and the
area with normal skin sensation. Transparent paper is used to
copy this area and save for further patch applications.
2.3. Assessment of Pain. A numerical pain rating scale
(NPRS), ranging from 0 to 10 points, is used to assess the pain
level, with 0 indicating no pain and 10 indicating the worst
imaginable pain. Patients are asked to rate their pain scores
at the following times: at first visit, before patch application,
throughout the treatment procedure (see Section 2.6), at one
week after application, and at 4–6 weeks after treatment. One
week after treatment, patients are contacted by telephone to
assess discomfort, heat pain, and any analgesics used.
2.4. QuantitativeThermal Testing. AQTT profile is routinely
obtained in all patients at the following time points: pre-
treatment, one to two weeks after the first consultation and
at PeNP diagnosis. The QTT test is always performed in
the same room under the same environmental conditions.
We determine warm sensation threshold (WST) and heat
pain threshold (HPT) values, first in the normal contralateral
skin area and then in the affected skin area, using the limits
method [16]. The QTT test is performed using the pathway
9.0 cm2 thermode (MEDOCLtd., Israel) [17, 18].The baseline
temperature is set at 32∘C (center of neutral range), with
a cut-off temperature of 50∘C and a ramp rate of 1∘C/s
for warm threshold and 1.5∘C/s for heat pain. Patients are
instructed to press a button (which returns the temperature
to baseline) as soon as they perceive a warm or heat pain
sensation. For each threshold, the test is repeated from 3
(minimum) to 5 (maximum) times. Based on these tests,
a mean threshold value and standard deviation (SD) are
automatically calculated.
2.5. Treatment with Capsaicin 8% Patch. On the day of
treatment, the patients are told to eat a small meal (either
breakfast or lunch, as appropriate) before presenting at the
outpatient clinic. Topical local anaesthetic is applied for 75–
90 minutes before procedure. The anaesthetic cream is then
removed and the skin washed and dried. Afterwards, the
patch is cut to fit using the previously created transparent
sheet and applied to the patient’s skin for 30 to 60 minutes,
depending on the location. Health professionals and patients
are required to wear the recommended protection at all times
[8]. Once the patch has been removed, the area is cleanedwith
the gel provided by the patch manufacturer and the patient is
discharged.
2.6.Management of Treatment-RelatedDiscomfort. As part of
the treatment protocol, patients are asked to rate their actual
discomfort level using the NPRS.This is reevaluated every 20
minutes for one-hour procedures and every 15minutes for 30-
minute procedures. Blood pressure is also taken after every
pain rating. After the CP8% treatment has finished, patients
are discharged and given two sheets ofmalleable frozen gel for
home use. Instructions are also provided for extra treatment
with nonsteroidal oral analgesics.
2.7. Efficacy. Treatment response (i.e., pain relief)was defined
as a > 30% decrease in the NPRS from baseline to the
posttreatment assessment at weeks 4–6. In cases in which
the difference is exactly 30% or when the patient is unable
to rate pain relief with the NPRS, then treatment efficacy
is determined by asking the patient to estimate overall
improvement and willingness to repeat treatment.
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2.8. Statistical Analysis. The statistical analysis was per-
formed with the VassarStats online software [19]. To check
for differences in demographic data between responders
and nonresponders, we performed a two sample 𝑡-test for
independent samples for parametric values.𝜒2 was calculated
for responders. Given that the total sample size was barely
enough to perform the chi-squared test for some groups, the
Fisher exact test was also calculated in these cases.
2.9. Difference in QTT for the Target and Control Areas. The
patient sample was highly heterogenous due to variability in
the following factors/conditions: time elapsed from injury
to treatment; the use of multiple different concomitant
medications; use of drugs acting on central nervous system
(CNS) (i.e., antidepressants, psychoactive, or anticonvul-
sants) (see Table S4 in Supplementary Material available
online at https://doi.org/10.1155/2017/7425907); different pain
localizations involving one or several nerve territories. For
these reasons, we were unable to compare out sample to
normalized data reported elsewhere [20].
Since all patients in this sample had localized pain only,
we used the contralateral asymptomatic healthy area as a
control.TheQTT profiles at the target PeLNP area were com-
pared to the corresponding QTT profile at the contralateral
area. As part of the routine treatment procedures, both WST
and HPT values were assessed at baseline in the treatment
(PeLNP site) area and at the asymptomatic contralateral site.
Differences between the WST and HPT values in the target
and control areas were considered not significant when there
was a crossover between mean results (±1.96 SD) for the
measurement on both areas; when this occurred, the painful
area was considered to present normal thermal sensations. By
contrast, if there was no crossover, we considered the WST
(or HPT) for the treatment site to be significantly different
(higher or lower) from the contralateral site.
3. Results
3.1. Patients. We initially identified a total of 65 patients
diagnosed with PeLNP who had been treated with CP8%
during the 2010–2013 period. Of these, 10 were excluded from
the study for varying reasons: five were excluded because
the contralateral area was not asymptomatic (contralateral
pain in 5 cases and midline pain in 2 cases). Three other
patients were excluded for the following reasons: one had an
interventional pain procedure between treatment and assess-
ment, another developed a recurrence requiring radiotherapy
before the follow-up visit; and QTT data was not available
in the third case. As a result, the final sample consisted
of 55 patients. Table 1 shows the demographic parameters
organized according to responders and nonresponders. The
mean age was 59 years old (range 32–82 years). There were
no significant differences between the groups in terms of
gender, age, DN4, or pretreatment NPRS scores. Of the 24
responders, the pain improvement lasted for > 6 months in
5 patients, where in 2 of them pain relief lasted for almost 12
months, while another patient fully recovered from the pain.
For the other 19 patients (see Table 1), 7 of themhad pain relief
over 90 days, whereas 8 recovered between 60 and 90 days,
and only 4 had recovery for less than 60 days or less (always
more than 45 days). In all patients, the DN4 score was ≥ 4.
3.2. QTT Profile. Figure 1 is a flowchart of QTT profiles for
WST andHPT values at the pain area versus the contralateral
asymptomatic area. None of the patients presented a signif-
icantly high WST combined with a significantly low HTP,
nor did any present the opposite (i.e., significantly low WST
and significantly high HPT). Among the nonresponders, 4
patterns emerged.
Pattern 1. There were no significant differences in WST or
HPT between the painful area and the control areal.
Pattern 2. WST is not significantly different between the
control and target areas while the HPT value showed signifi-
cant abnormal thermal sensations (either high or low) at the
painful area.
Pattern 3. HPT presents no significant differences while the
WST value shows significant abnormal thermal sensations
(either high or low) in the painful area.
Pattern 4. Both WST and HPT values present significant
differences between the two areas (both high or both low).
BothWST andHPT show abnormal thermal sensations at the
pain site.
Two distinct groups were identified based on differences
inQTT profiles for responders and nonresponders (Tables S1,
S2, and S3). One group presented nonhomogenousWST and
HPT results while the second group had homogenous WST
and HPT results (Figure 2).
(i) Homogenous Profile Group. The first group presented
homogenous WST and HPT profiles, defined as either the
presence of significant differences in the same direction (both
high or both low) in WST and HPT values between the
PeLNP region and the asymptomatic contralateral area or no
significant difference in these measures (both the treatment
and control sites normal).
(ii) Nonhomogenous Group. The second group consisted
of patients with nonhomogenous WST and HPT profiles,
defined as the presence of significant differences between the
PeLNP area and the contralateral site in only one (eitherWST
or HPT) measure but not the other.
3.3. Predictors of Response to Treatment
3.3.1. Demographics: Aetiology and Duration of Pain. There
were no baseline differences between responders and non-
responders in terms of gender, age, DN4 scores, etiological
diagnosis, or NPRS. There was a slightly larger number
of females in the nonresponse group, but this was not
statistically significant.
3.3.2. Patterns and Responders. Table 2 shows the sensitivity,
specificity, positive and negative predictive values, and posi-
tive and negative probability coefficients. As Table 2 shows, 24
4 Pain Research and Treatment
Table 1: Demographic data according to treatment response.
Variable Nonresponders Responders 𝑝 value
Gender (female/male ratio) 19/12 13/11 0.28
Age (mean) 60.26 (14.25) 58.42 (13.28) 0.62
DN4 score 5.90 (1.37) 5.39 (1.29) 0.24
Pretreatment NPRS 7.21 (1.20) 6.89 (1.75) 0.79
Posttreatment NPRS 7.08 (1.29) 2.92 (1.38) n.a.
Duration of improvement, months (mean) b 72.89 (24.68)a n.a.





DN4 = Douleur Neuropathique 4 Questionnaire. NPRS = numerical pain rating scale (0–10). CPSP = chronic postsurgical pain. PHN = postherpetic neuralgia.
CRPS = complex regional pain syndrome type I. n.a. = not applicable. Gender and type of PeNP for the whole patient sample. For the others, numbers are
given as means. Standard deviation in parenthesis. a = calculated for 19 patients. The other 5 were excluded due to reporting > 6 months of improvement. b
= nonresponders had no days of improvement, most of whom reported no improvement at all. c = posttrauma and CRPS were not taken into account for the







No differences R: 7, NR: 13
Hypoalgesia R: 1, NR: 1






Hyperesthesia R: 2, NR: 0
Pattern 4
n.s.
(9) Hypoesthesia R: 8, NR: 1
Hyperesthesia with hyperalgesia R: 2, 
NR: 6














Figure 1: QTT profiles flowchart and responders/nonresponders to treatment.WST = warm sensation threshold. HPT = heat pain threshold.
n.s. = not significant differences between painful and asymptomatic areas. ↑ = painful area with a significantly high difference versus the
asymptomatic contralateral area. ↓ = painful area with a significantly low difference versus the asymptomatic contralateral area. In parenthesis
(), number of patients with this profile. R = responders to treatment with capsaicin patch. NR = nonresponders to treatment with capsaicin
patch. Clinical definitions such as hypoalgesia, hyperalgesia, hypoesthesia, and hyperesthesia are given to improve reading comprehension
to understand the comparison versus the contralateral asymptomatic area; these QTT are not comparable to normalized published data.
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Table 2: Contingency table.
Total No improvement Improvement
PPV = 76% 17 4 13a Nonhomogenous (WST ̸=HPT)
NPV = 71% 38 27 11 Homogenous (WST = HPT)
55 31 24 Total
E = 87% S = 54%
NLR = 0.52 PLR = 4.2
Contingency table for the QTT profiles and patterns observed as a predictor of improvement after application of the capsaicin 8% patch. WST ̸= HPT:
nonhomogenous results for warm sensation threshold and heat pain threshold in the peripheral neuropathic pain area versus the contralateral control area,
with one measurement (either WST or HPT) showing a significant difference between the control and treatment areas while the other measurement (either
WST or HPT) is not significantly different between the two sites. WST = HTP: both warm sensation threshold and heat pain threshold had homogenous test
results in the pain and control areas: bothwere either significantly higher or lower, or neither was significantly different. S: sensibility. E: specificity. PPV: positive
predictive value. NPV: negative predictive value. PLR: Positive Likelihood Ratio. NLR: Negative Likelihood Ratio. a𝜒2 = 8.94 (𝑝 = 0.0028). Fisher exact test












Figure 2: QTT profile groups identified after matching responder
and nonresponders to treatment with capsaicin patch. WST: warm
sensation threshold. HPT: heat pain threshold. n.s.: no significant
difference between pain site and asymptomatic contralateral area
for the thermal test. s.↑: the thermal test was significantly higher
in the painful area versus the asymptomatic contralateral area. s.↓:
the thermal test was significantly lower in the painful area versus
the asymptomatic contralateral area. H.s↑/H.s↓: HPT for the painful
area was significantly higher when WST was significantly higher
or lower when WST was significantly lower than the asymptomatic
contralateral area.
patients improved after a single application of CP8% whereas
31 did not improve. The 𝜒2 was 8.94 (𝑝 = 0.0028) and Fisher
exact test (two tailed) was 𝑝 = 0.0014 for patients who
responded to treatment and had nonhomogenous WST and
HPT values.
4. Discussion
At present, there are no reliable predictors of response
to treatment with capsaicin for analgesia. Given that the
application of capsaicin causes heat sensation, the aim of
this study was to assess quantitative thermal testing (QTT)
profiles in a group of patients with localized peripheral
neuropathic pain (PeLNP) treated with topic capsaicin, to
determine whether different QTT profiles could predict
treatment outcomes. We did a retrospective analysis of 55
patients treated between 2010 and 2013 for PeLNP, where,
as part of the routine treatment procedures, both warm
sensation threshold (WST) and heat pain threshold (HPT)
values were assessed at baseline in the treatment (PeLNP
site) area and the asymptomatic contralateral site. From
the analysis, two different groups were identified based on
their QTT profile. The first group presented homogenous
WST and HPT profiles, defined as either the presence of
significant differences in the same direction (both high or
both low) inWST andHPT values between the PeLNP region
and the asymptomatic contralateral area or no significant
difference in these measures (both the treatment and control
sites normal). The second group consisted of patients with
nonhomogenous WST and HPT profiles, defined as the
presence of significant differences between the PeLNP area
and the contralateral site in only one (either WST or HPT)
measure but not the other. Most patients (27/31, 87.1%) with a
homogenous profile were nonresponders. By contrast, more
than half of the patients (13/24, 54.2%) with a nonhomoge-
nous profile were responders (𝑝 = 0.0028). Although the
reasons for this difference are not clear, we hypothesize
patients with a partial loss of cutaneous nerve fibers or
receptors aremore likely to respond to treatment. By contrast,
when severe nerve damage or normal cutaneous sensations
are present, the pain is likely due to central sensitization and
thus not responsive to capsaicin.
Potentially damaging mechanical, thermal, and chemical
stimuli are detected by nerve endings called nociceptors
found in the skin and other organs [21, 22]. The largest group
of such nociceptors is the family of channels of the transient
receptor potential (TRP) [23]. Within the TRP family, there
are four different molecules (TRPV1, TRPV2, TRPV3, and
TRPV4) that respond to different degrees of temperature
increase, ranging from the perception of heat all the way up
to harmful levels [24–26].
TRPV1 is a nonselective, ligand-dependent cationic chan-
nel that can be activated by a series of exogenous and endoge-
nous physical and chemical stimuli, including temperatures
above 43∘C, low pH (in acid medium), endocannabinoids
anandamide and N-arachidonyl-dopamine, or chemicals
such as capsaicin (8-methyl-N-vanillyl-6-nonenamide) [27,
28], allowing the passage of different monovalent or divalent
cations [29, 30]. TRPV1 is mainly expressed in peripheral
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nervous system (PNS) neurons such as the dorsal root
ganglion (DRG) and in C and A𝛿 sensory fibers [27, 28, 31].
In patients with neuropathic pain (NP), TRPV1 is expressed
through the nociceptive pathway, from unmyelinated axons
in the skin to the back of the spinal cord [22]. Transduction
of the signal is achieved through the influx of sodium and
calcium. In this way, the neurons expressing these receptors
are depolarized [32, 33]. Many of the ligands that come into
contact with TRPV1 possess synergistic effects, channel them
integrally, and lead to a response or signal transduction [34].
In primary afferents, the nociceptors, upon activation,
trigger the release of various peptides, including glutamate,
neurokinin A, substance P, and the peptide related to the
calcitonin gene in the dorsal horn (DH) of the spinal cord
[35–38]. These neurotransmitters then trigger a series of sig-
nals that contribute to the activation of second-order sensory
neurons, such as spinothalamic tract cells (STT) [39, 40] and
other projection neurons. This causes the transmission of
nociceptive information to the brain. In addition, signals are
released that will activate GABAergic inhibitory interneurons
of the DH [40, 41]. Together, the information that reaches
the central nervous system (CNS) is interpreted as a burning
pain or an itch, in addition to causing the peripheral release
of proinflammatory substances that sensitize other neurons
and subsequently give rise to other stimuli [32].
Multiple inflammatory stimuli increase the expression
of TRPV1 and even increase the density of axons positive
for TRPV1 [42–46]. A priori, this suggests that TRPV1
is involved in the pathogenesis of hyperalgesia and other
pathological sensations. TRPV1 antiserum reduces thermal
allodynia and hyperalgesia in diabetic mice [47]. In addi-
tion, TRPV1 antagonists reduce inflammation and NP [48].
Despite these known effects, the importance of TRPV1 in
the pathogenesis of NP or peripheral neuropathies remains
controversial [22]. It has been suggested that TRPV1 has
an effect on the pathogenesis of nerve pain secondary to
nerve damage [49]. However, some studies indicate that the
TRPV1 receptor is not directly involved in the pathogenesis
of PeNP [28, 50] and other studies suggest that the TRPV1
receptor does not contribute to the triggered hyperalgesia in
situations of nerve injury [51]. In addition, numerous studies
have reported conflicting data about the density of TRPV1
and the degree of nerve damage [52–57]. Taken altogether,
these facts suggest that TRPV1 is not useful as a specific
marker in cases of nerve injury [22]. However, more recent
studies suggest that recipients of the same TRP family present
patterns suggestive of an association between NP and injury,
specifically, TRPV3 [58–60] and TRPV4 [46, 61]. Despite the
aforementioned controversy, TRPV1 receptors continue to
offer great therapeutic possibilities [62]. Given the ongoing
research in this area, it seems likely that, in the near future, we
will come to better understand the pharmacological potential
of TRPV1.
Capsaicin is a well-known exogenous activator of TRPV1.
Its pain relief effect is believed to be due to the activation
of small diameter afferent nerve fibers and specialized DRG
neurons that respond to many different noxious stimuli [63].
Capsaicin also mediates some actions of the endocannabi-
noid CB1 anandamide, which shares the same intracellular
binding site as TRPV1 [64, 65]. Thus, capsaicin stimulates
nociceptors and generates signal transmission to the brain,
which interprets the signal as pain [40]. As a result, the
application of capsaicin can desensitize the nerve terminals
of nociceptors by inducing long-term desensitization after
prolonged exposure. This desensitization allows the use of
capsaicin as an analgesic, and its mechanism of action is
based on the destruction of axons and, ultimately, of the DRG
nociceptors [66].
Cutaneous injection of capsaicin activates the TRPV1
receptors, causing an influx of sodium and calcium ions into
the cytoplasm of nociceptive neurons expressing that recep-
tor [64]. At the capsaicin injection site, primary mechanical
hyperalgesia and heat develop due to desensitization of the
afferents containing TRPV1 receptors [67–69]. In a larger
area surrounding the injection site, secondary mechanical
hyperalgesia and allodynia take place. The primary effects
of mechanical hyperalgesia and heat are believed to be
attributable to sensitization of the primary afferent noci-
ceptors [70]. However, at the site of secondary mechanical
hyperalgesia and allodynia, the degree of excitability of first-
order neurons is normal [40, 71, 72], implying that allodynia
and secondary hyperalgesia depend on the CNS, such as STT.
This effect is called central sensitization (CS) [33, 37, 40, 73–
81]. This suggests that NP is maintained by second- or third-
order neurons without a significant effect on the peripheral
nerve afferents [82].
Previous studies [13] have found that patients can be
grouped into various subgroups based on their response to
treatment with CP8%. This finding suggests that response
variability may be related to different pain mechanisms. One
patient group in that study presented high variability in
pain rating scores (i.e., mixed treatment response), whereas
the low variability group were nonresponders. The authors
suggested that the lack of response in this group could be
due to long-term chronic pain and the presence of severe
central plastic changes. By contrast, high variability in pain
rating scores could be due to a more recent development
of chronic pain status, as occurred in the CPSP group in
our study. Given that the EMA authorised treatment in
Europe for any condition with PeNP (except for diabetes), we
included patients with a wide variety of etiological diagnoses
(Table 1). Many of our patients had a diagnosis of CPSP,
which is not surprising given that this diagnosis accounts
for a large percentage of patients with PeNP [83, 84]. Our
findings suggest that CPSP patients may be more responsive
toCP8% than other groups.Martini et al. suggested that other
factors or predictors related to the treatment of patients with
chronic pain could enhance the ability to predict therapeutic
efficacy. Specific patterns in the QST profile may represent
specific phenotypes that have a greater or lesser probability
of treatment response. Indeed, several authors have already
shown that specific tests in the QST profile may represent a
specific population that is more likely to respond to therapy.
Eisenberg et al. [10] showed that the magnitude of heat pain
thresholds predicts the magnitude of the decrease in pain
intensity in response to oxycodone treatment (the greater
the heat pain threshold, the greater the opioid effect; 𝑅2 =
0.17) in healthy volunteers. Yarnitsky et al. [85] showed in
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a sample of patients with painful diabetic neuropathy that
patients with less efficient conditioned pain modulation have
greater analgesic responses to duloxetine (𝑅2 = 0.39).
The present study involves a cohort of patients treated
as part of routine clinical practice at a single center. We
retrospectively identified patients who had been treated with
CP8% and who also had a pretreatment QTT profile test
available. The main aim was to determine the existence (or
not) of a QTT pattern that could help identify those patients
likely to respond to CP8% treatment. The main limitation to
this study is its retrospective design.Other limitations include
the relatively small number of patients, which precluded
the use of subgroup analysis. We found no differences
in demographics (gender, age, and etiological diagnosis of
PeNP) between responders and nonresponders. We assume
that the demographic data represent a normal distribution
although this cannot be verified. Another limitation is that
the number of responders in our study was larger than
expected in the context of the high NNT reported in other
studies [86]. There are several possible reasons for this,
particularly the calculation of the NNT itself [87]. Clinical
trials were not compared to placebo, but rather to low-dose
capsaicin (0.075%), which has been shown to be effective for
the relief ofNP [88].TheNNTcould have beenmiscalculated,
making it difficult to compare NNTs from a study that used
a low-dose control to NNTs in studies using inert placebos
[89]. Another reason for the high response rate in our study
could be the inclusion of patients with variable etiological
diagnoses for PeNP, such asCPSP. In addition, a placebo effect
cannot be ruled out, especially given that controlled trials
have described a placebo response rate ranging from 23%
to 36% [7, 90]. Another limitation is that the medical team
was not blinded, and this may have introduced bias into the
patient assessment at follow-up.
We found that the clinical effects of CP8% were better in
patients with nonhomogenous QTT profiles. These patients
showed a significantly higher response rate than patients
with homogenous QTT profiles. This difference may be
due to incomplete nerve damage in these patients, leading
to an imbalance in the sensitive inputs to second-order
neurons from peripheral receptors and to the presence of
ectopic discharges on nerve endings. If so, pain in these
patients may be purely peripheral, with no additional CS
mechanisms. Capsaicin application in these patients could
eliminate the factor resulting in dysaesthesia when they
activate the remaining TRPV1 receptors, desensitizing the
nerve terminals of nociceptors by destroying the remaining
axons and nociceptors.
By contrast, the group of patients with homogeneous
QTT profiles had little or no clinical improvement. These
patients either had no peripheral damage (normally func-
tioning nociceptors) or may have had complete peripheral
nerve damage (absent or nonfunctional nociceptors). When
no peripheral nerve damage is present, there should not be
any receptor loss and thus there should be no differences
in WST/HPT values between the painful area and the
asymptomatic contralateral area.The opposite should also be
true: in the case of complete peripheral nerve damage, nearly
complete loss of receptors is to be expected, meaning that
both warmth and heat sensations are likely to significantly
differ between the painful and control areas. Thus, in both
of these cases (i.e., complete peripheral nerve damage and no
damage at all), the QTT tests should be homogenous, with
capsaicin therapy unlikely to be efficacious in either of these
two groups. Indeed, our results point in this direction. Pain
in these patients could be due to CSmechanisms, with inputs
multiplied at the DH as explained above; that is, the origin
of the pain in these patients is probably less peripheral and
more central. For this reason, the capsaicin is less effective in
providing pain relief.
In the 3rd pattern identified (i.e., no significant differ-
ences in the HPT but significant differences in the WST) the
hypoesthesia (high WST only) subgroup presented a better
response rate (8 responders versus only 1 nonresponder).
Although we were unable to perform a subgroup analysis due
to the small sample size, these findings support the hypothesis
developed by Malmberg et al. [6], who argued that the
foremost psychophysical manifestation of topical capsaicin
treatment is a reduced sensitivity to heat stimuli. This is
the expression of an elevated-warmth detection threshold,
corresponding to a loss of cutaneous sensory nerve fibers.
Overall, andwithin the aforementioned study limitations,
our results seem to confirm previous reports. Höper et al. [12]
evaluated sensory neuropathic abnormalities (painDETECT
questionnaire), finding that the presence of burning and
pressure-evoked pain was weakly associated with treatment
response. They argued that thermal hyperalgesia is difficult
to interpret and thus cannot serve as a predictor of response,
which could be ascribed to the fact that the painDETECT
questionnaire does not distinguish between cold and heat-
evoked pain. Consequently, they concluded that data on heat-
evoked pain, which is very likely TRPV1 receptor-dependent,
would be preferable to predict treatment response to CP8%.
Edwards et al. [91] found that the HPT values in the affected
area and at the corresponding contralateral side predicted
the effect of morphine and methadone on pain in patients
with PHN. We found a similar association between certain
QTT profiles and capsaicin response when we compared the
pain site to the contralateral asymptomatic area. Gustorff
et al. [11] identified potential differences in the sensory
profiles—particularly the pressure pain threshold and degree
of allodynia—of patients with PeNPwho responded to CP8%
and those who did not. In that study, the authors were
unable to find warm hyperesthesia of heat hyperalgesia in
responders, and they found similar WST/HPT profiles at
baseline for both responders and nonresponders. By contrast,
we looked at QTT profiles from a different point of view,
using the contralateral asymptomatic area as the only control
reference.
Despite the findings described above, it is possible that
unilateral PeLNP may be associated with bilateral changes
in PNS [92]. Thresholds measured on the contralateral side
in PeLNP patients may not represent basal pain sensitivity.
For this reason, we considered the homogeneity of QTT pro-
files rather than clinical symptoms (i.e., heat hyperalgesia).
Martini et al. [13] found one group of patients with PeLNP
whose pain could be attributed to a rigid and fully manifested
chronic pain process with severe CS plastic changes that
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were unresponsive to therapy. In our study, we were aware
that central or bilateral peripheral changes could occur—
even though our sample consisted of patients with PeLNP—
and for this reason we considered differences between the
treatment and contralateral areas to be significant only when
there was no crossover between mean results (±2 SD).
Using these criteria, two patterns were found for responders
and nonresponders when we examined profile homogeneity.
For instance, a significantly differently low HPT (i.e., heat
hyperalgesia) with no significant difference in WST was
considered nonhomogeneous. By contrast, if the WST was
also significantly different between the control and treatment
areas, then the QTT profile was considered homogenous.
Based on our results, it appears that patients who show a
nonhomogenous profile in terms ofWST andHPT values are
significantly more likely to respond to capsaicin treatment,
probably due to the presence of incomplete nerve damage.
Nevertheless, these findings need to be confirmed in a
prospective controlled blinded study, preferably with a large
sample to enable subgroup analysis to better identify theQTT
profile of responders.
Additional Points
What is already known about this topic? (i) There are no
reliable predictors of response to treatment for localized
neuropathic pain. (ii) Although some studies have attempted
to identify predictors of treatment response, none have
proven reliable.
What does this study add? (i) Quantitative thermal tests
may help to predict which patients will respond to capsaicin
patch treatment. (ii) Patients with partial damage to periph-
eral nerves may respond better to the mechanism of action of
topical capsaicin than patients with completely damaged or
undamaged peripheral nerves.
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